Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 19 Issue 8, August 2022

Hepatitis can’t wait, inspired by the Perspective on p533

Cover design: Laura Marshall

Comment

  • Only 12 high-income countries are on track to meet the World Health Organization’s goal of eliminating hepatitis C as a public health threat by 2030, and micro-elimination opportunities in high-risk populations in settings such as hospitals are often overlooked. We propose ten steps to eliminate hepatitis C in hospitals.

    • José Luis Calleja
    • Antonio Aguilera
    • Jeffrey V. Lazarus
    Comment

    Advertisement

Top of page ⤴

Research Highlights

Top of page ⤴

News & Views

  • New data demonstrate racial and ethnic disparities in access to prescription medications in persons with chronic liver disease in the USA. Here, we discuss potential health equity solutions that address structural and social determinants of health to mitigate liver health inequities in access to liver disease pharmacotherapies.

    • Ani Kardashian
    • Lauren D. Nephew
    News & Views
  • Owing to its simplicity, dextran sulfate sodium (DSS)-induced colitis is one of the most widely used mouse models of colitis. However, the severity of inflammation varies from one experiment to another. In a new study, Forster and colleagues have provided new insights into the DSS model by revealing specific microbial taxa that underlie disease variability.

    • Nicolas Benech
    • Harry Sokol
    News & Views
Top of page ⤴

Reviews

Top of page ⤴

Perspectives

Top of page ⤴

Amendments & Corrections

Top of page ⤴

Search

Quick links